Log In
Print
BCIQ
Print
Print this Print this
 

Copegus, ribavirin (RG964)

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSynthetic nucleoside analog
Molecular Target Unknown
Mechanism of ActionUnknown
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHepatitis C virus (HCV)
Indication DetailsImprove viremia associated with compensated cirrhosis related to HCV infection; Treat chronic hepatitis C virus (HCV) genotype 1, 2 and 3 infection in treatment naïve patients; Treat chronic hepatitis C virus (HCV) infection in interferon-naïve patients; Treat hepatitis C virus (HCV) infection; Treat hepatitis C virus (HCV) infection in treatment-naïve patients
Regulatory Designation

Partner

Chugai Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today